L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile

Felix Kf Kommoss, Anthony Karnezis, Friedrich Kommoss, Aline Talhouk, Florin Andrei Taran, Annette Staebler, C. Blake Gilks, David G. Huntsman, Bernhard Krämer, Sara Y. Brucker, Jessica N. McAlpine, Stefan Kommoss

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


Background: The newly developed Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) has consistently been shown to be prognostically significant in endometrial carcinomas (EC). Recently, we and others have demonstrated L1 cell-adhesion molecule (L1CAM) to be a significant indicator of high-risk disease in EC. In the current study, it was our aim to determine the prognostic significance of aberrant L1CAM expression in ProMisE subgroups in a large, single centre, population-based EC cohort. Methods: ProMisE (POLE; MMR-D; p53 wt/NSMP; p53 abn) classification results from a cohort of 452 EC were available for analysis. L1CAM expression was studied by immunohistochemistry on whole slides. Correlations between clinicopathological data and survival were calculated. Results: Expression of L1CAM was most frequent in p53 abnormal tumours (80%). L1CAM status was predictive of worse outcome among tumours with no specific molecular profile (p53 wt/NSMP) (p < 0.0001). Among p53 wt/NSMP EC, L1CAM remained a significant prognosticator for disease-specific survival after multivariate analysis (p = 0.035). Conclusion: L1CAM status was able to significantly stratify risk among tumours of the large p53 wt/NSMP ProMisE subgroup of EC. Furthermore, our study confirms a highly significant correlation between mutation-type p53 immunostaining and abnormal L1CAM expression in EC.

Original languageEnglish (US)
JournalBritish Journal of Cancer
StateAccepted/In press - Jan 1 2018
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile'. Together they form a unique fingerprint.

Cite this